HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
[Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
OBJECTIVE To study the efficacy and safety of estradiol and drospirenone tablets ( Angeliq ) in treatment of menopausal symptoms among postmenopausal Chinese healthy women . METHODS Total 244 postmenopausal Chinese healthy women who had moderate to severe hot flushes were r and omly assigned into estradiol and drospirenone ( observation group , n = 183 ) or placebo group ( n = 61 ) by the ratio of 3:1 for 16 weeks in this r and omized multi-center double-blind placebo-controlled study . During the trial , the follow-up visits were conducted at week 4 , 8 , 12 , 16 of treatment and 2 weeks after treatment respectively . Height , weight , vital signs , hot flushes , other relevant menopausal symptoms and vaginal bleeding were observed in each follow-up visit , while the clinical global impression scale was assessed at 16 weeks as well . RESULTS It showed that hot flushes were reduced significantly more in observation group than that in placebo group ( P < 0.01 ) , although both treatments were effective . The absolute values of mean severity index of total hot flushes decreased by -0.6 ± 0.5 in observation group and -0.4 ± 0.4 in placebo group from baseline respectively , which reached significant difference ( P < 0.05 ) . However , the absolute values of mean severity index of moderate to severe hot flushes decreased by -0.6 ± 0.8 in observation group and -0.3 ± 0.6 in placebo group from baseline respectively , which had no significant difference ( P > 0.05 ) . After 16 weeks treatment , it also showed that estradiol and drospirenone had significant better efficacy than placebo on moderate to severe sweating , vaginal dryness and clinical global impression scale ( P < 0.01 ) . During the trial , blood pressure in observation group was stable . The rate of vaginal bleeding in observation group was higher than that in the placebo group , especially during the week 4 to week 8 when 48.9 % ( 87/178 ) in observation group and 10.7 % ( 6/56 ) in placebo group of patients bled . Although the cumulative amenorrhea rate of observation group was lower than that of placebo group in each cycle ( 28 days ) , it increased gradually along with duration of the treatment . The commonest adverse event in observation group was breast tenderness which accounted for 12.0 % ( 22/183 ) . The level of serum potassium was in the normal range in observation group mostly . Meanwhile , the other adverse events rate was low . Serious adverse events reported in this trial were assessed as not study drug related or as unlikely study drug related . CONCLUSION Estradiol and drospirenone tablets which could effectively alleviate menopausal symptoms in postmenopausal Chinese healthy women is a novel hormone replacement therapy regimen with high safety and efficacy
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .